|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2015
|
|
gptkbp:ATCCode
|
C10AX13
|
|
gptkbp:brand
|
gptkb:Repatha
|
|
gptkbp:CASNumber
|
1256937-27-5
|
|
gptkbp:contraindication
|
hypersensitivity to evolocumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Amgen
|
|
gptkbp:effect
|
reduces LDL cholesterol by up to 60%
reduces risk of coronary revascularization
reduces risk of myocardial infarction
reduces risk of stroke
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
11-17 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
evolocumab
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines_(not_included_as_of_2023)
|
|
gptkbp:indication
|
cardiovascular risk reduction
statin intolerance
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
IgG2 monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
PCSK9 inhibitor
|
|
gptkbp:molecularWeight
|
~141 kDa
|
|
gptkbp:monitors
|
gptkb:lipid_panel
|
|
gptkbp:notableFor
|
gptkb:DESCARTES_trial
gptkb:FOURIER_trial
|
|
gptkbp:patent
|
gptkb:Amgen
|
|
gptkbp:pharmacokinetics
|
linear at low doses, nonlinear at high doses
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:prescribedWith
|
gptkb:ezetimibe
statins
|
|
gptkbp:prescriptionForm
|
prefilled syringe
autoinjector
on-body infusor
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
back pain
injection site reactions
upper respiratory tract infection
nasopharyngitis
flu-like symptoms
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:PCSK9
|
|
gptkbp:UNII
|
8A5I2R4F2K
|
|
gptkbp:usedFor
|
lowering LDL cholesterol
treatment of hyperlipidemia
treatment of homozygous familial hypercholesterolemia
treatment of heterozygous familial hypercholesterolemia
|
|
gptkbp:bfsParent
|
gptkb:PCSK9_inhibitors
gptkb:PCSK9_protein
gptkb:PCSK9_gene
gptkb:Repatha
|
|
gptkbp:bfsLayer
|
7
|